Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS study

Archives of Ophthalmology

Volumn 124, Issue 11, 2006, Pages 1532-1542

  Heier, Jeffrey S ^a   Boyer, David S ^b   Ciulla, Thomas A ^c   Ferrone, Philip J ^d   Jumper, J Michael ^e   Gentile, Ronald C ^f   Kotlovker, Debbi ^g   Chung, Carol Y ^g   Kim, Robert Y ^g  

^a OPHTHALMIC CONSULTANTS OF BOSTON   (United States)

^b RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^c MIDWEST EYE INSTITUTE   (United States)

^d Long Island Vitreoretinal Consultants   (United States)

^e WEST COAST RETINA MEDICAL GROUP   (United States)

^f NEW YORK MEDICAL COLLEGE   (United States)

^g GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; RANIBIZUMAB;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ADULT; ANXIETY; ARTICLE; BLEEDING; BLEPHARITIS; BLURRED VISION; CEREBROVASCULAR ACCIDENT; CHICKENPOX; CHOLELITHIASIS; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; COMPRESSION FRACTURE; CONJUNCTIVAL HEMORRHAGE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DEHYDRATION; DEMENTIA; DEPRESSION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE INFLAMMATION; EYE IRRITATION; EYE PAIN; FEMALE; FOREIGN BODY REACTION; GASTROENTERITIS; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HIP FRACTURE; HUMAN; HYPERTENSION; INCIDENCE; INTESTINE OBSTRUCTION; INTRAOCULAR PRESSURE ABNORMALITY; IRIDOCYCLITIS; IRITIS; LIMB PAIN; LUNG TUMOR; MALE; MULTICENTER STUDY; OCULAR FIBROSIS; OSTEOARTHRITIS; PHASE 2 CLINICAL TRIAL; PHOTODYNAMIC THERAPY; PNEUMONIA; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; RETINA TEAR; ROTATOR CUFF RUPTURE; SIDE EFFECT; SINUSITIS; SUBRETINAL NEOVASCULARIZATION; THROMBOSIS; THYROID CANCER; TRANSIENT ISCHEMIC ATTACK; UNSTABLE ANGINA PECTORIS; URINARY TRACT INFECTION; UVEITIS; VIRAL RESPIRATORY TRACT INFECTION; VISUAL ACUITY; VISUAL DISORDER; VITREOUS BODY DETACHMENT; VITREOUS DISEASE; VITREOUS FLOATERS;

EID: 33750314559     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.124.11.1532     Document Type: Article

References (27)

1. Congdon N, O'Colmain B, Klaver CC, et al; Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol. 2004;122:477-485.
2. Bressler NM. Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901.
3. Friedman DS, O'Colmain BJ, Munoz B, et al. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572.
4. Resnikoff S, Pascolini D, Etya'ale D, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82:844-851.
5. Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.
6. Barbazetto I, Burdan A, Bressler NM, et al. Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment: TAP and VIP report No. 2. Arch Ophthalmol. 2003;121:1253-1268.
7. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials. Arch Ophthalmol. 1991;109:1109-1114.
8. Macular Photocoagulation Study Group. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Arch Ophthalmol. 1994;112:489-499.
9. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials: TAP report. Arch Ophthalmol. 1999;117:1329-1345.
10. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP report 2. Arch Ophthalmol. 2001;119:198-207.
11. Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351:2805-2816.
12. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol. 1999;293:865-881.
13. Rosenfeld PJ, Heier JS, Hantsbarger G, Shams N. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology. 2006;113:632.e1. doi:10.1016/j.ophtha.2006.01.027.
14. Heier JS, Antoszyk AN, Pavan PR, et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology. 2006;113:633-642.
15. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-1053.
16. Rosenfeld PJ, Brown DM, Heier JS, et al; for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431.
17. Brown DM, Kaiser PK, Michels M, et al; for the ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444.
18. Visudyne [US package insert]. Basel, Switzerland; Novartis AG; 2002.
19. Hogan MJ, Kimura SJ, Thygeson P. Signs and symptoms of uveitis, I: anterior uveitis. Am J Ophthalmol. 1959;47:155-170.
20. Nussenblatt RB, Whitcup SM, Palestine AG. Uveitis: Fundamentals and Clinical Practice. 2nd ed. St Louis, Mo: Mosby; 1996.
21. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005;23:3697-3705.
22. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
23. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy, I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ. 1994;308:81-106.
24. Holz FG, Jorzik J, Schutt F, Flach U, Unnebrink K. Agreement among ophthalmologists in evaluating fluorescein angiograms in patients with neovascular age-related macular degeneration for photodynamic therapy eligibility (FLAP-study). Ophthalmology. 2003;110:400-405.
25. Friedman SM, Margo CE. Choroidal neovascular membranes: reproducibility of angiographic interpretation. Am J Ophthalmol. 2000;130:839-841.
26. Avastin [package insert]. South San Francisco, Calif: Genentech Inc; 2004.
27. Skillings JR, Johnson DH, Miller K, et al. Arterial thromboembolic events (ATEs) in a pooled analysis of 5 randomized, controlled trials (RCTs) of bevacizumab (BV) with chemotherapy [Abstract 3019]. J Clin Oncol. 2005;23(suppl):196s.